Repligen | RGEN - Debt


Repligen reported $542.21M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Agilent USD 3.35B 55M Sep/2025
Align Technology USD 121.27M 1.75M Sep/2025
Bio Techne USD 260M 40M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Bruker USD 2.01B 426.8M Sep/2025
Charles River Laboratories USD 2.63B 157.4M Sep/2025
Danaher USD 18.42B 1.56B Dec/2025
Dentsply International USD 2.48B 14M Sep/2025
General Electric Aerospace USD 20.49B 344M Dec/2025
Henry Schein USD 3.44B 83M Sep/2025
Illumina USD 2.58B 22M Sep/2025
IQVIA Holdings USD 15.72B 767M Dec/2025
Mettler Toledo International USD 2.21B 25.94M Sep/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
OraSure Technologies USD 782K 465K Jun/2024
Pacific Biosciences Of California USD 892.24M 653K Dec/2023
Pfizer USD 60.85B 78M Sep/2025
Repligen USD 542.21M 146.65M Dec/2025
Revvity USD 3.37B 5.86M Sep/2025
Standard Biotools USD 27.39M 1.23M Sep/2025
Thermo Fisher Scientific USD 35.68B 451M Sep/2025
Waters USD 1.49B 52.2M Sep/2025
West Pharmaceutical Services USD 202.8M 100K Dec/2025